Prise en charge de l’hidrosadénite suppurée chez des groupes de patients particuliers
Résumé
L’hidrosadénite suppurée est une maladie inflammatoire chronique de la peau qui se déclare à un jeune âge. Les traitements médicaux aux propriétés anti-inflammatoires sont le pilier thérapeutique. Les tétracyclines, la rifampicine en association avec la clindamycine et l’adalimumab sont les approches thérapeutiques standard. De nombreux autres médicaments sont toutefois requis dans la prise en charge de la maladie en l’absence d’une réponse à ces traitements ou à cause de leurs contre-indications.
Références
Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81:91-101.
Alhusayen R, Shear NH. Pharmacologic Interventions for Hidradenitis Suppurativa. Am J Clin Dermatol. 2012 Oct 1;13(5):283-91.
Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S42-6
Dauden E, Lazaro P, Aguilar MD, et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatology Venereol. 2018 Jan;32(1):129-144.
Perng P, Zampella JG, Okoye GA. Management of hidradenitis suppurativa in pregnancy. J Am Acad Dermatol. 2017;76:979-89.
Smilack JD. The tetracyclines. Mayo Clin Proc. 1999 Jul;74(7):727-9.
Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med. 1965;38:359-77.
Wenk RE, Gebhardt FC, Bhagavan BS, et al. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med. 1981;26:135-41.
Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: A population-based, case-control study. Am J Obstet Gynecol. 2001;184:1289-96.
McGregor JA, French JI, Seo K. Adjunctive clindamycin therapy for preterm labor: Results of a double-blind, placebo-controlled trial. Am J Obstet Gynecol. 1991;165:867-75.
Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: A population-based case-control teratologic study. Eur J Obstet Gynecol Reprod Biol. 2001;97:188-92.
Berkovitch M, Diav-Citrin O, Greenberg R, et al. First-trimester exposure to amoxycillin/clavulanic acid: a prospective, controlled study. Br J Clin Pharmacol. 2004;58:298–302.
Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: A meta-analysis. Am J Obstet Gynecol. 1995;172:525–9.
Bookstaver PB, Bland CM, Griffin B, et al. A Review of Antibiotic Use in Pregnancy. Pharmacotherapy. 2015 Nov;35(11):1052-62.
Snider DE, Layde PM, Johnson MW, Lyle MA. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis. 1980 Jul;122(1):65-79.
Bothamley G. Drug treatment for tuberculosis during pregnancy: Safety considerations. Drug Saf. 2001;24(7):553-65.
Liu J, Murray AM, Mankus EB, et al. Adjuvant use of rifampin for refractory intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2018;132:678-81.
Rezai S, Gallo D, Payero E, Henderson CE. Adjuvant Use of Rifampin for Refractory Intrahepatic Cholestasis of Pregnancy. Obstet Gynecol. 2019;133:384-5.
Puchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation: A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr. 2019 Jan;131(1-2):29-44.
Burmester GR, Landewé R, Genovese MC, et al. Adalimumab long-term safety: Infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417.
Johansen CB, Jimenez-Solem E, Haerskjold A, et al. The use and safety of TNF inhibitors during pregnancy in women with psoriasis: A review. Int J Mol Sci. 2018 May 3;19(5):1349.
Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. Br Med J. 2007;334:1218-20.
Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228-233.
Chen WT, Chi CC. Association of Hidradenitis Suppurativa with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155:1022-7.
Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential Association Between the Oral Tetracycline Class of Antimicrobials Used to Treat Acne and Inflammatory Bowel Disease. Am J Gastroenterol. 2010;105:2610-6.
Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013 May;57(5):2326-32.
Gionchetti P, Rizzello F, Lammers KM, et al. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol. 2006;12:3306-13.
Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: A randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014 Feb;63(2):292-9.
Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205-17.
Ghias MH, Johnston AD, Kutner AJ, et al. High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020 May;82(5):1094-1101.
Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81:702-8.
Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa. J Eur Acad Dermatology Venereol. 2012;26:911-4.
Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174:839-46.
Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa. Dermatology. 2020;236(1):21-24.
Casseres RG, Kahn JS, Her MJ, Rosmarin D. Guselkumab in the treatment of hidradenitis suppurativa: A retrospective chart review. J Am Acad Dermatol. 2019;81:265-7.
Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s disease. J Dermatolog Treat. 2021 Mar;32(2):261-263.
Grossberg LB. A Case Report of Successful Treatment of Crohn’s Disease and Psoriasis With Guselkumab. Inflamm Bowel Dis. 2019;25:e84-e84.
Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol. 2016;75:1059-62.
Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology. 2001;121:255-60.
Vekic DA, Woods J, Lin P, Cains GD. SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature. Int J Dermatol. 2018;57:10-8.
Souza DA, De Souza A, Solomon GE, et al. SAPHO Syndrome Associated With Hidradenitis Suppurativa Successfully Treated with Infliximab and Methotrexate. Bull NYU Hosp Jt Dis. 2011;69(2):185-7.
Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444-7.
Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693-700.
Vernero M, Astegiano M, Ribaldone DG. New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab. Am J Gastroenterol. 2019;114:179-80.
Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: A retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473–9.
Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis. J Am Acad Dermatol. 2014;71:1144–50.
Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis – Results from a multicenter national prospective study. J Rheumatol. 2014;41:490–4.
Rondags A, Arends S, Wink FR, et al. High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation. Semin Arthritis Rheum. 2019;48:611–7.
Schneeweiss MC, Kim SC, Schneeweiss S, et al. Risk of Inflammatory Arthritis after a New Diagnosis of Hidradenitis Suppurativa. JAMA Dermatology. 2020;156:342–5.
Smith CJ, Sayles H, Mikuls TR, Michaud K. Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: Prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Res Ther. 2011;13:R168.
Suarez-Almazor ME, Belseck E, Shea B, et al. Sulfasalazine for treating rheumatoid arthritis. Cochrane Database Syst Rev. 1998. doi:10.1002/14651858.cd000958
Lima AL, Karl I, Giner T, et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol. 2016;174:514–21.
Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982;69:494–7.
Machan A, Azendour H, Toufik H, et al. Leflunomide-Induced Hidradenitis Suppurativa. 2020. doi:10.1155/2020/3549491
Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375:422–34.
Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–4.
Taylor PC, Feldmann M. Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:578–82.
Pratt AG, Isaacs JD. Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. Best Pract Res Clin Rheumatol. 2014;28:651–9.
Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa a randomized clinical trial. JAMA Dermatol. 2016;152:52–9.
Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa – Rapid response to canakinumab (anti-IL-1ß). Eur J Dermatol. 2013;23:408–10.
Houriet C, Seyed Jafari SM, Thomi R, et al. Canakinumab for severe hidradenitis suppurativa: Preliminary experience in 2 cases. JAMA Dermatol. 2017;153:1195–7.
Sun N, Ro T, Jolly P, et al. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J Clin Aesthet Dermatol. 2017 Sep;10(9):36–38.
Tekin B, Salman A, Ergun T. Hidradenitis suppurativa unresponsive to canakinumab treatment: a case report. Indian J Dermatol Venereol Leprol. 2017;83:615-617.
Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2005. doi:10.1002/14651858.cd000189.pub2
Deckers IE, Van Der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol. 2015;72:485–8.
Liy-Wong C, Pope E, Lara-Corrales I. Hidradenitis suppurativa in the pediatric population. J Am Acad Dermatol. 2015;73:S36–41.
Mikkelsen PR, Jemec GBE. Hidradenitis Suppurativa in Children and Adolescents: A Review of Treatment Options. Pediatr Drugs. 2014;16:483–9.
Tetracycline – FDA prescribing information, side effects and uses [internet]. URL https://www.drugs.com/pro/tetracycline.html [accessed on April 14, 2020].
Scheinfeld N. Hidradenitis suppurativa in prepubescent and pubescent children. Clin Dermatol 2015; 33:316–9.
Verdolini R, Clayton N, Smith A, et al. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatology Venereol 2013; 27:1101–8.
Min HP, Kinra S, Ward KJ, et al. Metformin for obesity in children and adolescents: A systematic review. Diabetes Care. 2009; 32:1743–5.
Randhawa HK, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatology 2013; 149:732–5.
Lee A, Fischer G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas J Dermatol 2015; 56:192–6.
Kraft JN, Searles GE. Hidradenitis suppurativa in 64 female patients: retrospective study comparing oral antibiotics and antiandrogen therapy. J Cutan Med Surg 2007; 11:125–31.
Adalimumab (Professional Patient Advice) – Drugs.com [WWW Document]. URL https://www.drugs.com/ppa/adalimumab.html [accessed on April 14, 2020].
Dayan JR, Dolinger M, Benkov K, et al. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center. J Pediatr Gastroenterol Nutr 2019; 69:61–7.
Baldassano R. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 2003; 98:833–8.
Hochberg Z. Mechanisms of Steroid Impairment of Growth. Horm Res Paediatr 2002; 58:33–8.
Bernheim O, Colombel JF, Ullman TA, et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013; 62:1523–8.
Singh J, Saag K, Jr SB, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016; 68 (1): 1–26. .
Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol 2019; 5:1774–8.
Join-Lambert O, Coignard-Biehler H, Jais J-P, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother 2016; 71:513–20.
Menter A, Tyring S, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. ElsevierURL https://www.sciencedirect.com/science/article/pii/S0190962207014375 [accessed on April 13, 2020].
Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials. Br. J. Dermatol. 2008; 159:274–85.
Gottlieb A, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. ElsevierURL https://www.sciencedirect.com/science/article/pii/S019096220400742X [accessed on April 13, 2020].
Casseres R, Prussick L, … PZ-J of the A, 2020 undefined. Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial. ElsevierURL https://www.sciencedirect.com/science/article/pii/S0190962220302097 [accessed on April 13, 2020].
Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol 2019; 80:80–8.
Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol 2019; 180:1009–17.
BAKER H, RYAN TJ. GENERALIZED PUSTULAR PSORIASIS. Br J Dermatol 1968; 80:771–93.
Hsiao JL, Antaya RJ, Berger T, et al. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: A case series and literature review. Arch Dermatol 2010; 146:1265–70.
Ah-Weng A, Langtry JAA, Velangi S, et al. Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005; 30:669–71.
Dessinioti C, Katsambas A, Antoniou C. Hidradenitis suppurrativa (acne inversa) as a systemic disease. Clin Dermatol 2014; 32:397–408.
Wollina U. Clinical management of pyoderma gangrenosum. Am. J. Clin. Dermatol. 2002; 3:149–58.
Brown RE, Lay L, Graham D. Bilateral pyoderma gangrenosum of the hand: Treatment with dapsone. J Hand Surg Am 1993; 18:119–21.
Miranda M. Pyoderma gangrenosum treated with sulfasalazine and dapsone. Indian J Dermatol Venereol Leprol 2002; 68:160–1.
Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients. Dermatology 2011; 222:342–6.
Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatology Venereol 2019; 33:19–31.
NJ R, RD P. Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. Acta Derm Venereol 1990; 70:538–9.
PD S. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 1996; 57:315–9.
WS L, WF B. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis 1978; 21:535–8.
Mrcp JBJ, Tan SV, Graham-Brown RAC, Pembroke AC. The successful use of minocycline in pyoderma gangrenosum-a report of seven cases and review of the literature. J Dermatolog Treat 1989; 1:23–5.
Matis W, Ellis C, … CG-A of, 1992 undefined. Treatment of pyoderma gangrenosum with cyclosporine. jamanetwork.comURL https://jamanetwork.com/journals/jamadermatology/article-abstract/554286 [accessed on April 14, 2020].
Elgart G, Stover P, Larson K, et al. Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients. ElsevierURL https://www.sciencedirect.com/science/article/pii/019096229170016U [accessed on April 14, 2020].
Goldberg N, Ottuso P, surgery JP-P and reconstructive, 1993 undefined. Cyclosporine for pyoderma gangrenosum. europepmc.orgURL https://europepmc.org/abstract/med/8416543 [accessed on April 14, 2020].
Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol 2016; 75. doi:10.1016/j.jaad.2016.06.001.
Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005; 152:1059–61.
Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006; 5:e8.
Brooklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut 2006; 55:505–9.
Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol. Ther. 2016; 29:482–3.
Low ZM, Mar A. Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab. Australas J Dermatol 2018; 59:131–4.
Acquitter M, Plantin P, Kupfer I, et al. Anakinra improves pyoderma gangrenosum in psoriatic arthritis: A case report. Ann. Intern. Med. 2015; 163:70–1.
Lin Z, Hegarty JP, Lin T, et al. Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. Inflamm Bowel Dis 2011; 17:E41–2.
